← Back to Search

Estrogen Blockade Imaging for Pulmonary Arterial Hypertension (TYEGER Trial)

Phase 2
Waitlist Available
Led By Eric D Austin, MD, MSCI
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 13 years or older
Group 1: PH Patients with precapillary PH (PAH) identified based on previous genotyping and diagnostic criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

TYEGER Trial Summary

This trial will test whether or not a therapy that blocks estrogen in the lungs can improve 1 year outcomes for a subset of PAH patients with higher levels of estrogen and estrogen receptors in their lungs.

Who is the study for?
This trial is for people aged 13 or older with pulmonary arterial hypertension (PAH), those with PH due to heart disease, and healthy individuals without cardiopulmonary issues. It excludes anyone with Type 1 Diabetes, polycystic ovarian disease, certain cancers, or those on hormone therapies.Check my eligibility
What is being tested?
The study uses an ESR-specific PET scan to investigate estrogen levels and estrogen receptors in the lungs of PAH patients. The goal is to identify candidates for new treatments that target these factors in hopes of halting the progression of PAH.See study design
What are the potential side effects?
Since this trial involves diagnostic imaging rather than a drug intervention, side effects are minimal but may include discomfort from the scanning process or reactions related to contrast agents used during PET scans.

TYEGER Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have been diagnosed with a specific type of high blood pressure in the lungs called precapillary pulmonary hypertension.
Select...
People with pulmonary hypertension caused by heart problems, diagnosed by specific tests.

TYEGER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To correlate lung ESR density with pulmonary vascular resistance (PVR)
Secondary outcome measures
Survival at one year

TYEGER Trial Design

1Treatment groups
Experimental Treatment
Group I: ESR-specific PET ScanExperimental Treatment1 Intervention
Specific Aim: To test the hypothesis that among PAH patients, higher lung ESR density associates with a more severe hemodynamic profile and worse 1 year outcomes. Study Design: Enroll 20 randomly selected subjects from each group (PAH vs. control)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ESR-specific PET scan
2021
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
856 Previous Clinical Trials
672,126 Total Patients Enrolled
10 Trials studying Pulmonary Arterial Hypertension
2,429 Patients Enrolled for Pulmonary Arterial Hypertension
Eric D Austin, MD, MSCIPrincipal InvestigatorVanderbilt University Medical Center

Media Library

ESR-specific PET scan Clinical Trial Eligibility Overview. Trial Name: NCT04280523 — Phase 2
Pulmonary Arterial Hypertension Research Study Groups: ESR-specific PET Scan
Pulmonary Arterial Hypertension Clinical Trial 2023: ESR-specific PET scan Highlights & Side Effects. Trial Name: NCT04280523 — Phase 2
ESR-specific PET scan 2023 Treatment Timeline for Medical Study. Trial Name: NCT04280523 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the ESR-specific PET scan a secure diagnostic method for individuals?

"While ESR-specific PET scan is not yet proven to be efficacious in clinical trials, there is some data suggesting the safety of the test which allows it to attain a score of 2."

Answered by AI

Is this research experiment accepting new participants?

"clinicaltrials.gov reports that this clinical trial is actively recruiting patients. It was first posted on the 5th of January 2021, and its details were recently updated on the 26th of January 2022."

Answered by AI

What is the participant count for this clinical trial?

"Affirmative, the available information on clinicaltrials.gov reflects that this experiment is actively searching for participants. It was initially posted in January 5th 2021 and revised most recently on January 26th 2022. 40 people are being sought out from a single site to take part in the study."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH
Eric Austin 2021. "TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04280523.
~16 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top